Scientists join forces to address key unanswered questions about immunity and COVID-19
3 September 2020
The research is critical to understanding the many unknowns around the novel virus
UK Scientists are launching a major new project to answer key questions on how the immune system interacts with COVID-19, in order to develop better treatments, diagnostics and vaccines.
The UK Coronavirus Immunology Consortium (UK-CIC) combines the expertise of scientists from 17 institutions including the University of York and will work to identify how the immune system responds to SARS-CoV-2 – the virus which causes COVID-19.
The research is critical to understanding the many unknowns around the novel virus – for example, why it makes some people sick and not others, what constitutes effective immunity and how long might that immunity last.
To address the need for rapid and effective progress in our knowledge of COVID-19 and the immune system, the UK Coronavirus Immunology Consortium has received £6.5million of funding over 12 months from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR). This represents the largest immunology grant awarded to tackle the COVID-19 pandemic.
UK-CIC aims to deliver meaningful benefits for public health by providing insights critical for improving patient care, developing new therapies, assessing immunity within the population and developing diagnostics and vaccines.
UK-CIC sets out to answer five key questions that will help the global coronavirus response:
- Why do people experience different symptoms from COVID-19 and what role does the immune system play in this?
- What constitutes immunity to COVID-19 and how long does it last?
- How does the immune system respond to SARS-CoV-2 on a molecular and cellular level and what happens when the immune system overreacts?
- Can infection with other mild coronaviruses (which cause the common cold) protect you from catching COVID-19 or will it make you more ill?
- How does SARS-CoV-2 hide from the immune system?
Paul Kaye, Professor of Immunology at Hull York Medical School at the University of York, said: "Our research team at York, together with colleagues in Cambridge, Cardiff and Newcastle, will be taking the lead on addressing the question of how our immune system contributes to the damage caused to different body organs after SARS-CoV-2 infection and whether treatments that modulate specific immune responses might therefore be beneficial. We will also be looking at the role the immune system plays in determining variation in susceptibility to primary infection with COVID-19 and how this varies across the life course.
"The coronavirus pandemic poses a global challenge of enormous magnitude and this nationally-coordinated effort will enable us to work together, harnessing technologies and expertise not available within a single institute, to bring about meaningful benefits for patients."
The Consortium will collaborate closely with ISARIC-4C, an internationally-leading project already underway to examine the immune profile of hospitalised patients with COVID-19, and is supported by the British Society for Immunology.
Professor Paul Moss, UK-CIC Principal Investigator of the Consortium from the University of Birmingham, said: "Understanding the complexities of the immune response to SARS-CoV-2 is key to successfully developing new diagnostics, treatments and vaccines against COVID-19. UK-CIC will see the UK immunology community come together in an unprecedented way to answer questions that are crucial in helping us control this pandemic, such as how effective immunity is developed and why individuals respond differently to the disease.
"Immunologists are at the forefront of efforts to tackle the coronavirus pandemic and the UK is a world-leader in immunology research. It’s an honour to lead this consortium to deliver a co-ordinated and agile national research programme to build our knowledge of this disease, which will translate into meaningful benefit for patients. There is so much that we still need to learn about how the novel coronavirus interacts with our immune system and, with this investment, we have a unique opportunity to answer these key questions and hasten effective pandemic control."